![Fred Grossman](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Fortuna: 13 062 $ al 31/05/2026
Dr. Fred Grossman is a President & Chief Medical Officer at Coya Therapeutics, Inc. Dr. Grossman was previously employed as a Chief Medical Officer by Empyrean Neuroscience, Inc., a Chief Medical Officer by Mesoblast Ltd., a Chief Medical Officer by Mesoblast, Inc., a President & Chief Medical Officer by Glenmark Pharmaceuticals Ltd., a President & Chief Medical Officer by Glenmark Pharmaceuticals Inc., USA, a Head-Clinical Development & Medical Affairs by Sunovion Pharmaceuticals, Inc., and a Global Head-Medical Affairs Organization by Bristol Myers Squibb Co. He also served on the board at Reunion Neuroscience, Inc. He received his undergraduate degree from Hahnemann University.
| Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
|---|---|---|---|---|
COYA THERAPEUTICS, INC. 0,01 % | 01/05/2026 | 2.710 ( 0,01 % ) | 13 062 $ | 31/05/2026 |
| Empresas | Cargo | Inicio |
|---|---|---|
| COYA THERAPEUTICS, INC. | Presidente | 17/07/2023 |
| Empresas | Cargo | Fin |
|---|---|---|
Empyrean Neuroscience, Inc.
 Empyrean Neuroscience, Inc. Pharmaceuticals: OtherHealth Technology Engages in genetic engineering of fungi and plants to create neuroactive therapeutics | Director Técnico/Científico/I+D | 01/01/2023 |
| MESOBLAST LIMITED | Director Técnico/Científico/I+D | 02/02/2022 |
| GLENMARK PHARMACEUTICALS LIMITED | Presidente | 01/01/2019 |
Glenmark Pharmaceuticals Inc., USA
 Glenmark Pharmaceuticals Inc., USA Pharmaceuticals: MajorHealth Technology Manufactures and distributes generic pharmaceutical products | Presidente | 01/08/2018 |
Sumitomo Pharma America, Inc.
 Sumitomo Pharma America, Inc. Pharmaceuticals: MajorHealth Technology Manufactures pharmaceuticals for oncology, CNS, urology and rare diseases | Corporate Officer/Principal | 01/10/2015 |
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
| Empresas privadas | 10 |
|---|---|
Bristol Myers Squibb Co.
 Bristol Myers Squibb Co. Pharmaceuticals: MajorHealth Technology Manufactures and markets biopharmaceuticals products | Health Technology |
Sumitomo Pharma America, Inc.
Sumitomo Pharma America, Inc. Pharmaceuticals: MajorHealth Technology Manufactures pharmaceuticals for oncology, CNS, urology and rare diseases | Health Technology |
Mesoblast, Inc.
 Mesoblast, Inc. Pharmaceuticals: MajorHealth Technology Manufactures and distributes biopharmaceutical products | Health Technology |
Glenmark Pharmaceuticals Ltd.
 Glenmark Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Develops and manufactures pharmaceuticals | Health Technology |
Mesoblast Ltd.
 Mesoblast Ltd. BiotechnologyHealth Technology Engages in the development and commercialization of biological and adult stem cells products | Health Technology |
Hahnemann University
 Hahnemann University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Glenmark Pharmaceuticals Inc., USA
Glenmark Pharmaceuticals Inc., USA Pharmaceuticals: MajorHealth Technology Manufactures and distributes generic pharmaceutical products | Health Technology |
Coya Therapeutics, Inc.
 Coya Therapeutics, Inc. BiotechnologyHealth Technology Operates as a clinical-stage biotechnology company that focuses on research and development of therapies to enhance the function of regulatory T cells | Health Technology |
Empyrean Neuroscience, Inc.
Empyrean Neuroscience, Inc. Pharmaceuticals: OtherHealth Technology Engages in genetic engineering of fungi and plants to create neuroactive therapeutics | Health Technology |
Reunion Neuroscience, Inc.
 Reunion Neuroscience, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical-stage biopharmaceutical company that develops FDA-approved serotonergic psychedelic therapeutic solutions for underserved mental health disorders | Health Technology |
Selecciona tu edición
Toda la información financiera adaptada al ámbito nacional.
